Quantcast
Channel: Experts
Viewing all articles
Browse latest Browse all 84

The FDA's panel of experts said its COVID-19 vaccine approval rules aren't strict enough, and could lead to vaccines being rushed out

$
0
0

vaccine trial

Summary List Placement

The Food and Drug Administration's (FDA) panel of experts questioned the safety and efficacy of its own rules around emergency COVID-19 vaccine approval at an advisory meeting Thursday.

The FDA's vaccine advisory board, made up of external experts in infectious diseases, met Thursday to discuss the agency's standards for a coronavirus vaccine.

Many the panel members voiced concerns about a vaccine being rushed out, and later proving unsafe or ineffective against coronavirus.

This could ultimately undermine public confidence in COVID-19 vaccines for years to come, they said.

The first test of these rules could come in late November, when Pfizer has said it plans to submit its vaccine for emergency approval.

In particular, experts on the panel were worried about the FDA's rule that manufacturers must wait two months after giving a final dose to patients before applying for approval. This is not long enough, the experts said.

Amanda Cohn, chief medical officer at the National Center for Immunization and Respiratory Diseases, said in the meeting: "Very rarely do we look at [vaccine efficacy] so shortly after completing a series."

Diana Zuckerman of the National Center for Health Research said the vaccine trials "have serious design flaws." They are too focused around treating mild infections, and may not show whether the vaccines treat severe strains of the virus, she said.

Read more: The top 5 takeaways from the first meeting of the FDA's expert vaccine group, including plans for vetting, distributing, and tracking COVID-19 vaccines

Hayley Altman-Gans, a panel member and pediatrics professor at Stanford University Medical Center, said the trials "haven't gone far enough" in terms of safety.

Archana Chatterjee, advisory panel member and dean of Chicago Medical School, told the committee the public are concerned about the safety of coronavirus vaccines, adding: "What we're being asked to do is to build this plane as we fly it."

The meeting came just before the FDA approved Gilead Sciences' antiviral drug remdesivir to treat coronavirus patients.

Remdesivir, which was used to treat President Donald Trump's coronavirus infection, is the only antiviral drug approved to treat COVID-19 patients. 

SEE ALSO: Gilead's remdesivir just got the first FDA approval to be used as a treatment for coronavirus patients

SEE ALSO: The top 5 takeaways from the first meeting of the FDA's expert vaccine group, including plans for vetting, distributing, and tracking COVID-19 vaccines

SEE ALSO: The UK is hopeful of rolling out a coronavirus vaccine 'soon after Christmas'

Join the conversation about this story »

NOW WATCH: We tested a machine that brews beer at the push of a button


Viewing all articles
Browse latest Browse all 84

Latest Images

Trending Articles





Latest Images

<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>
<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596344.js" async> </script>